Posted by Michael Wonder on 08 Jan 2018
NICE to look again at Pfizer’s Besponsa after appeal
3 January 2018 - The blood cancer medicine was originally turned down on cost-effectiveness grounds.
Pfizer has persuaded NICE to take another look at leukaemia drug Besponsa, which was rejected by the agency in 2017.
Last August, NICE turned down Besponsa (inotuzumab ozogamicin) for routine use on the National Health Service for adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia on cost-effectiveness grounds. The disease affects around 760 patients in the UK, and is a particularly aggressive type of leukaemia with high unmet need and a poor prognosis.
